Overview

BMS - Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Dapagliflozin in Type 1 Diabetes

Status:
Completed
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
To obtain safety and tolerability information in patients with type 1 diabetes where Dapagliflozin is added on to Insulin (for 14 days)
Phase:
Phase 2
Details
Lead Sponsor:
AstraZeneca
Collaborator:
Astra Zeneca, Bristol-Myers Squibb
Treatments:
Dapagliflozin